These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Statins and osteoporosis: a clinical review. Gonyeau MJ Pharmacotherapy; 2005 Feb; 25(2):228-43. PubMed ID: 15767237 [TBL] [Abstract][Full Text] [Related]
8. Are beta-blockers useful in the prevention of osteoporotic fractures? Pérez-Castrillón JL; De Luis DA; Duenas-Laita A Eur Rev Med Pharmacol Sci; 2009; 13(3):157-62. PubMed ID: 19673165 [TBL] [Abstract][Full Text] [Related]
9. Bone mineral density and prediction of non-osteoporotic disease. Tremollieres F; Ribot C Maturitas; 2010 Apr; 65(4):348-51. PubMed ID: 20079983 [TBL] [Abstract][Full Text] [Related]
10. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Toussaint ND; Elder GJ; Kerr PG Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295 [TBL] [Abstract][Full Text] [Related]
12. Osteoporosis: differences and similarities in male and female patients. Lane JM; Serota AC; Raphael B Orthop Clin North Am; 2006 Oct; 37(4):601-9. PubMed ID: 17141018 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Burnett JR; Vasikaran SD Ann Clin Biochem; 2002 May; 39(Pt 3):203-10. PubMed ID: 12038594 [TBL] [Abstract][Full Text] [Related]
14. [Coronary heart disease and osteoporosis: factors related to development of both diseases]. Nowicka G; Panczenko-Kresowska B Przegl Lek; 2007; 64(3):153-8. PubMed ID: 17941467 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
16. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988 [TBL] [Abstract][Full Text] [Related]
17. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Coulson KA; Reed G; Gilliam BE; Kremer JM; Pepmueller PH J Clin Rheumatol; 2009 Jun; 15(4):155-60. PubMed ID: 19363452 [TBL] [Abstract][Full Text] [Related]
18. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645 [TBL] [Abstract][Full Text] [Related]
19. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009 [TBL] [Abstract][Full Text] [Related]